The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.60
Bid: 13.50
Ask: 13.70
Change: -0.45 (-3.20%)
Spread: 0.20 (1.481%)
Open: 14.05
High: 13.85
Low: 13.50
Prev. Close: 14.05
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Cordiant Digital hails portfolio firm's deal with AMC

Thu, 02nd Mar 2023 14:47

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Cordiant Digital Infrastructure Ltd - Guernsey-based investor in core digital infrastructure, with a portfolio focused on data centres, telecommunications towers and fibre networks in the UK, EEA and US - Notes portfolio company CRA signs five-year agreement with AMC Networks International, a global provider of content such as Film+ and Sport1. Cordiant says the deal "underscores the new ways in which broadcast is being used in modern digital networks to improve efficiency, increase access and support sustainability initiatives." Malnay Levente, Chief Executive Officer of AMC Networks International says: "The Czech market is key for us in the Central European region and therefore securing wider distribution for our station to an increased number of households is a strategic step. CRA has been a great partner in this effort of ours, who will make it possible for us to take the next step and open a new window in the sphere of lifestyle entertainment television."

----------

Plant Health Care PLC - North Carolina, US-based provider of proprietary agricultural biological products and technology solutions focused on improving crop performance - Announces its biofungicide PHC279 receives approval from US Environmental Protection Agency. "Derived from natural proteins, PHC279 is the first product from the company's PREtec technology platform (vaccines for plants) that will be available to US farmers," Plant Health Care says. Company expects Wilbur-Ellis Agribusiness, a US retailer of agricultural products, to start selling PHC279 under the brand Obrona in 2023.

----------

Poolbeg Pharma PLC - London-based infectious disease-focused biopharmaceutical company - Announces positive data from POLB 001 LPS human challenge trial. POLB 001 is a bacterial lipopolysaccharide treatment being developed for severe influenza. Poolbeg says the treatment was shown to be safe, well tolerated and potent against systemic and localised inflammation. The results show POLB 001's potential as a "blockbuster treatment" for severe influenza, the firm says. Derek Gilroy, professor of Immunology at University College London, says: "POLB 001 has shown substantial promise in dampening the key players of harmful inflammation in both blood and tissues, acting where the immune system can do harm. These exciting data, and safety profile, support a role for POLB 001 beyond infectious diseases into treating a range of acute, aggressive immune responses."

----------

Totally PLC - Derby, England-based healthcare provider - For financial year 2023 ending March 31, expects earnings before interest, tax, depreciation and amortisation to be around GBP6.3 million, slightly above GBP6.2 million a year prior, but below market consensus. "The company has...been impacted by the combined impact of high inflation, national strikes, which increase pressure on services and scheduling, and clinical workforce shortages which increase reliance on agency staff for the delivery of urgent care services," Totally explains. Expects revenue to be in line with market consensus, and remains confident in its prospects.

----------

Touchstone Exploration Inc - upstream oil and gas company focused on Trinidad & Tobago - Completes drilling Royston-1X exploration well in Trinidad. Reaches total depth of 11,316 feet, finding "substantial sands" in the well in which it has an 80% operating working interest. Adds that well is being cased and prepared for production testing. CEO Paul Baay says the company is encouraged by the hydrocarbon indications interpreted from openhole wireline logs, saying: "We are encouraged by the Royston-1X drilling results yet remain cautiously optimistic until production testing is completed. Not only is this the deepest well we have drilled to date but it also is the deepest well drilled onshore Trinidad in the last 15 years. The fact that the well was drilled ahead of schedule and within our budget can be attributed to the best-in-class industry standards that Touchstone is driving within Trinidad, both through the introduction of new equipment, as well as additional expertise that we have added to our technical team."

----------

Vertu Motors PLC - Gateshead, England-based car dealership - Says trading in the five months to January 31 is in line with management expectations. Expects net debt as at February 28 to be between GBP80 million and GBP85 million, compared to a previous guidance of GBP100 million to GBP110 million. This compares to net cash of GBP16.2 million as at February 28, 2022. The company cites "strong operating cashflow and working capital management." Vertu Motors says 5-month like-for-like revenue is up 9.4% from a year prior, despite new retail vehicles volumes being down 5.4%. New fleet cars volumes are up 13%. CEO Robert Forrester says: "Used car margins have normalised back towards historical levels as we had expected and there are tentative signs of improving new car supply. The performance of our service and repair business has been strong." Vertu will release its annual results for the year that ended February 28 on May 10.

----------

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2024 16:39

Poolbeg Pharma celebrates full patent approval for Immunomodulator II

(Alliance News) - Poolbeg Pharma PLC on Wednesday said that it has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.

Read more
30 Apr 2024 16:43

Poolbeg agrees 12-month option over potential Behcet's treatment

(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX).

Read more
30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Mar 2024 11:10

Poolbeg Pharma to be granted US patent

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.

Read more
19 Feb 2024 14:22

Director dealings: Poolbeg Pharma co-founder ups stake

(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.

Read more
15 Feb 2024 16:02

TRADING UPDATES: Diversified Energy offers dividend alternative

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
12 Feb 2024 19:44

TRADING UPDATES: Katoro Gold launches fundraising, eyes board shake-up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
12 Feb 2024 14:37

Poolbeg upbeat on research into potential drug market

(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday, in preventing cancer immunotherapy-induced cytokine release syndrome (CRS) through oral delivery.

Read more
17 Jan 2024 13:58

Poolbeg Pharma hails POLB 001'S potential to treat CRS

(Alliance News) - Poolbeg Pharma PLC on Wednesday noted "promising" results for POLB 001's potential in treating cancer immunotherapy-induced cytokine release syndrome.

Read more
20 Dec 2023 20:00

TRADING UPDATES: K3 Business says cash balances ahead of forecast

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
20 Dec 2023 13:54

Poolbeg makes promising progress with RSV programme

(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its artificial intelligence (AI) programme.

Read more
21 Nov 2023 14:39

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
9 Nov 2023 16:57

IN BRIEF: Poolbeg Pharma appoints former Amryt executives to team

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Appoints a number of former executives of Amryt Pharma PLC to its leadership team. Poolbeg's Chair, Cathal Friel, co-founded both Poolbeg and Amryt Pharma.

Read more
17 Oct 2023 10:49

Poolbeg Pharma shares up on metabolic drug collaboration agreement

(Alliance News) - Poolbeg Pharma PLC on Tuesday said it has agreed to collaborate with an unnamed Nasdaq-listed biopharmaceutical company for the development of an optimised oral drug to treat a metabolic condition.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.